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Angiogenesis is a necessary process for tumor growth, progression and diﬀusion. In the last years many eﬀorts have been made to
understand the mechanisms necessary to the formation of new vessels in tumor tissue and how to integrate these ﬁndings in the
treatment of diﬀerent type of cancer. Thanks to these studies there are today many anti-angiogenic drugs with established activity
in cancer and approved in clinical practice. Head and neck cancer is a common tumor worldwide that often has advanced stage at
diagnosis and poor prognosis. Angiogenesis has a well recognized role in head and neck cancer progression and resistance to drugs
and radiotherapy and many clinical trials has been conducted with antiangiogenic agents in this disease, even if they often showed
limited eﬃcacy. In this review we summarize the main trials published about angiogenesis in head and neck cancer with particular
attention to factors involved in this process and the available data on the eﬃcacy of treatment with anti-angiogenic agents in this
disease.
1.Introduction
Squamous cell carcinoma of the head and neck (HNSCC) is
the sixth most common cancer with 500.000 diagnosis per
year worldwide [1]. Patients with locally advanced disease
have a chance of cure with multimodality treatments that
involves surgery, radiotherapy, chemotherapy, and, in the
last years, molecular targeted therapies [2]. Despite the
advances in the treatment of locally advanced disease, more
than 50% of patients will relapse. Furthermore, combining
surgery, radiotherapy, and chemotherapy often leads to
severe and permanent function deﬁcits with a negative
impact on patients’ quality of life. On the other hand,
patients with relapsed or metastatic disease have a worse
prognosis with an overall survival of approximately 7–10
months [3]. New therapeutic protocols and agents should
be developed to improve survival while limiting treatment-
related toxicities.
Angiogenesis, the process that leads to the formation of
new vessel, is a hallmark of tumor progression, and its role
has been studied in many cancer types including HNSCC.
Antiangiogenic agents are to date available and useful for the
treatment of many tumors. In HNSCC; however, few clinical
trials have yielded promising results when focusing on these
new agents.
This paper is aimed at evaluating the angiogenic factors
involved in HNSCC growth and progression and their
therapeutic implications.
2. Angiogenesis inHeadand Neck Cancer
Vascular endothelial growth factor A (VEGF-A) is the best
known agent that induce angiogenesis. It is a vascular per-
meability factor that belongs to the platelet-derived growth
factor (PDGF) superfamily, which also includes VEGF-B,
VEGF-C, VEGF-D, VEGF-E, and placental growth factor
(PlGF) [4]. Hypoxia induces VEGF expression through
the mediation of hypoxia-inducible factor (HIF-1α)[ 5].
There are many other factors involved in angiogenesis, such
as epidermal growth factor (EGF), PDGF, prostaglandins,
COX-2, and IL-6 [6]. The VEGF family of ligands plays its
role through cell surface receptor tyrosine kinases, VGFR-1,
VGFR-2, and VGFR-3 [7]. VEGFR-2 is the most important
one through which VEGF exerts its mitogenic, chemotactic,
and vascular permeabilizing eﬀects on endothelial cell [4].2 Journal of Oncology
Moreover, VEGF interacts with a family of coreceptors
called neuropilins (NRP-1 and NRP-2) [8, 9] that strengthen
the link between VEGF and its receptors increasing their
biological activity.
Overexpression of VEGF in HNSCC is associated with
more advanced disease, increased resistance to cytotoxic
agents, and poor prognosis [10–16]. In a meta-analysis of
12 studies including 1002 patients aﬀected by cancer of oral
cavity (70.8% of patients), pharynx (15.2%), and larynx
(14%), VEGF expression was evaluated, and its positivity
was associated with a twofold higher risk of death at 2 years
[17].
Hasina et al. [18] demonstrated that there are diﬀer-
ent molecular mechanisms by which each tumor induce
angiogenesis. Using sample collected from patients aﬀected
by HNSCC and sample of normal and dysplastic mucosa,
they conducted an immunohistochemical analysis and gene
expression proﬁling studies. They studied the expression
of cytokines (CK) such as VEGF, IL-8/CXCL8, HGF, and
FGF-2 in normal, dysplastic, and pathological tissues. These
CK are well-known mediators of HNSCC angiogenesis. The
authors observed that normal mucosa generally does not
expressVEGF,IL-8/CXCL8,FGF-2,andHGFandthat,where
present, the levels of these CKs are very low compared to
dysplastic and pathological mucosa. The same CKs are more
frequently expressed and at a higher levels in dysplastic
oral mucosa. The incidence and the intensity of expression
of VEGF, IL-8/CXCL8, FGF-2, and HGF are highest in
HNSCC samples. Moreover, they validated the presence of
two diﬀerent clusters in relation to angiogenesis in HNSCC
samples: tumors in Cluster A express high levels of VEGF
and FGF-2 and low levels of IL-8/CXCL8 and HGF and
are characterized by higher levels of microvessel density
than tumors in Cluster B, expressing on the contrary low
levels of VEGF and FGF-2 and higher levels of IL-8/CXCL8
and HGF. These data suggest that there are at least two
diﬀerent pathways in inducing angiogenesis in HNSCC.
This hypothesis has an important therapeutic implication.
In fact we can argue that the inhibition of a speciﬁc
molecular pathways can block the angiogenesis process, and
consequently the tumor growth, only if the target of the
therapy is expressed by the tumor cells. In the same study
the authors used three diﬀerent HNSCC cell lines with
diﬀerentlevelsofexpression ofVEGF thatwereinoculated in
nude mice. Then they treated the experimental models with
anti-VEGF antibody, with nonspeciﬁc human IgG antibody,
or with PBS (phosphate-buﬀered saline, a buﬀer solution
isotonic and nontoxic to cells). The growth of tumor with
high levels of VEGF was inhibited by anti-VEGF treatment
while not inﬂuenced by nonspeciﬁc IgG or PBS. On the
other hand anti-VEGF treatment had limited eﬀects on the
growth of tumor with low levels of VEGF. In this case no
diﬀerence in tumor volume was found compared to those
treated with nonspeciﬁc IgG or PBS. These data may have
very important implications in clinical practice and support
the need of better understanding the molecular alterations
in each speciﬁc tumor in order to better select patients for
targeted therapies.
3. Effect of Antiangiogenic Agents on
Xenograft Models
Several studies report the activity of diﬀerent molecules
directed against the angiogenic process in head and neck
models.
For example Miyazawa et al. [19] tested the eﬀect of
PTK/ZK (Vatalanib) on the initial stages of head and neck
tumor angiogenesis. PTK/ZK is a small molecule inhibitor
of VEGF receptors [20, 21]. The molecule has just been
tested by Kim et al. [22] in anaplastic thyroid carcinoma
xenografts in nude mice, and in that study it inhibited the
phosphorylation of VEGFR-2 in the endothelial cells and
reduced the microvessel density of the models. Miyazawa
et al. tested the eﬀects of PTK/ZK on neovascularization
in vitro and in vivo. They inoculated experimental mice
with diﬀerent HNSCC lines and treated them with the oral
administration of PTK/ZK or vehicle controls. They showed
that animals treated with the small VEGF receptor inhibitor
developedlowmicrovesseldensitycomparedtothosetreated
with vehicle control. Moreover, the models treated with
PTK/ZK had a slower tumor progression than controls, even
if the diﬀerence was not statistically signiﬁcant.
Several preclinical data about the association between
anti-EGFR and antiangiogenic treatments [23–25]a n d
betweenradiotherapyandantiangiogenicdrugs[26,27]have
been published recently. Moreover, in the last few years a
study conducted by Bonner et al. [28] demonstrated the eﬃ-
cacy of the association of radiotherapy and a target therapy
such as an anti-EGFR agent (cetuximab) in locally advanced
disease. Few studies investigated the intriguing combination
of the three approaches together. This association could be
very interesting in clinical practice because the production of
VEGF is inhibited, atleast in part, by anti-EGFR agentswhile
radiotherapy, through the induction of EGFR production
in irradiated cells, can lead to neovascularization. So the
combination of these three weapons could have synergistic
eﬀects.
In a study published in 2007, Bozec et al. [29]e v a l u -
ated the eﬃcacy of AZD2171, geﬁtinib, and radiotherapy.
AZD2171 is an inhibitor of VEGFR-2, VEGFR-1, and
VEGFR-3 in vitro [30], while geﬁtinib is an EGFR tyrosine
kinase inhibitor withantiangiogenic activity[23].Theeﬀects
of the combination of the two drugs on tumor growth and
of the combination of the drugs with radiotherapy were
tested on human head and neck tumor xenografts. The
investigators used a cell line, CAL33, that had high levels
of EGFR end VEGF. Mice inoculated with CAL33 tumors
were treated with vehicle alone, AZD2171 or geﬁtinib alone
or in combination, or with the two drugs combined with
radiotherapy. The treatment with AZD2171 and geﬁtinib
showed better antitumor eﬀects than either treatment alone,
but tumor regrowth after discontinuation was observed.
On the other hand, the triple combination (two drugs
plus radiotherapy) had the best antitumor eﬀects with a
prolonged activity after treatment discontinuation.
The same authors conducted a similar study [31]
using bevacizumab, monoclonal antibodies directed against
VEGF, erlotinib, an EGFR tyrosine-kinase inhibitor, andJournal of Oncology 3
radiotherapy on head and neck orthotopic models. They
tested the eﬃcacy of the three treatments, given alone or
in combination, on mice inoculated with CAL33 tumors.
Treatment with each single agent did not show a signiﬁcant
activity on tumor growth while the combination of the
three treatments had the best antitumor activity with supra-
additive eﬀects (combined ratios 2.3). An evaluation of
vascularization marker was conducted in the same study and
showed that the triple combination led to a decrease in cell
proliferation and neoangiogenesis (lower Ki-67 and VEGFR-
2 expression).
Then the same authors [32] tested the in vivo eﬃcacy
of the combination of sunitinib, a multitargeted tyrosine
kinase inhibitor with great anti-VEGF activity, cetuximab,
and radiotherapy. CAL33 cell lines were injected in mice
that were then treated with vehicle or cetuximab and/or
sunitinib and/or radiotherapy. In this study the treatments
given alone showed a signiﬁcant antitumor eﬀect compared
with controls. The best result on tumor growth was obtained
by the triple combination. In fact at the end of the treatment
with cetuximab, sunitinib, and radiotherapy, no tumor cells
were detectable in all treated animals (P<0.001 versus
control).
Myoung et al. [33] conducted a study using the com-
bination of paclitaxel and thalidomide on xenotransplanted
oral squamous cell carcinoma. Thalidomide is able to
inhibit neovascularization and tumor growth [34–37] while
paclitaxel is an antitumor agent with antiangiogenic activity
[38–41].Inthisstudyahumanoralsquamouscellcarcinoma
linewasinoculatedintonudemicesubsequentlytreatedwith
thalidomide, paclitaxel, or control vehicle. Paclitaxel showed
asigniﬁcantactivityontumorgrowth,whilethalidomidedid
not show any eﬀect. It is worthwhile noting that the two
drugs had remarkable eﬀects on the immunohistochemical
expression of VEGF and CD31, which was also reduced by
the administration of paclitaxel and thalidomide. A similar
reduction in the production of VEGF mRNA suggested a
good activity of these drugs against neovascularization. The
study suggests that the inhibition of angiogenesis is not
enough to suppress oral squamous cell carcinoma growth
and that probably antiangiogenic treatments have to be
integrated with other diﬀerent approaches.
4. Effect of AntiangiogenicAgents in
ClinicalTrials
Sorafenib and sunitinib are two tyrosine kinase inhibitors
with activity against VEGFR2, VEGFR3, and the PDGF
receptors that have been tested in diﬀerent studies in patients
with recurrent or metastatic HNSCC.
Three studies were reported with sunitinib. In the ﬁrst
study [42], 22 patients with recurrent or metastatic HNSCC
who had received no more than two prior chemotherapy
regimens were treated with sunitinib administered in 6-week
cycles at 50mg/day for 4 weeks followed by 2 weeks oﬀ.
Patients were divided into 2 cohorts according to the Eastern
Cooperative Oncology Group Performance Status (ECOG-
PS): patients with ECOG-PS 0-1 in cohort A, patients with
ECOG-PS 2 in cohort B. the primary endpoint was objective
tumor response for group A (15 patients) and feasibility
for group B (7 patients). In cohort A partial response (PR)
was reported in only one patient, while no response was
observed in cohort B. Stable disease (SD) was observed
in 25% of patients. The median overall survival (OS) was
21.1 weeks for patients in Cohort A and 19.1 weeks for
patients in cohort B. The main grade 3 hematologic toxicities
reported were lymphopenia (18%), neutropenia (14%), and
thrombocytopenia (5%). The only grade 4 hematologic
toxicity observed was thrombocytopenia occurring in one
patient. The most common nonhematologic grade 3 toxi-
cities were fatigue and anorexia (23% of patients). Grade
3 hypertension occurred only in one patient in cohort B.
Grade 4 hemorrhage was reported in one patient (gastro-
intestinal bleeding). Nonfatal hemorrhagic events were seen
in 8 patients; in 1 of these patients a superﬁcial tumor
bleeding was observed. Even if sunitinib was well tolerated,
accrual was closed at interim analysis as nonsigniﬁcant
antitumor activity was demonstrated.
Another study was conducted by Fountzilas et al. [43]
who treated 17 patients aﬀected by metastatic or recurrent
HNSCC with sunitinib in ﬁrst-line setting. The primary
endpoint of the study was objective response rate (ORR)
while the secondary endpoints included time to tumor
progression (TTP), OS, safety, and tolerability of sunitinib
as monotherapy. Fourteen patients were assessable for
response. Three patients (18%) had stabilization of disease
while 11 patients (65%) showed progression. No objective
responses were observed. Median TTP was 2.3 months, and
median OS was 4 months. The most common grade 3
toxicity was fatigue that occurred in 7 patients (41%), while
grade 3 hemorrhagic events were described only in 1 patient
(6%). Bleeding of any grade was reported in 10 patients
(59%). The study was discontinued because the drug proved
to be barely active.
These 2 studies showed that sunitinib 50mg/day for 4
weeks followed by 2 weeks rest is well tolerated but has no
signiﬁcant antitumor activity in monotherapy.
In the third study [44], sunitinib 37.5mg daily, given
continuously until disease progression or unacceptable tox-
icity, was tested on 38 patients with recurrent or metastatic
HNSCC refractory to platinum-based treatment or unﬁt
for platinum-based regimens. No more than 2 prior lines
of chemotherapy were permitted. The primary endpoint
was the rate of disease control (RDC), deﬁned as complete
response (CR) or PR or SD at 6 to 8 weeks after treatment
initiation. RDC was 50% (1 patient with PR and 18 patients
with SD). The median PFS was 2 months while the median
OS was 3.4 months. The most frequent grade 3/4 toxicities
were fatigue (32%), anorexia (16%), thrombocytopenia
(13%), and diarrhea (8%). Serious hemorrhagic events
of head and neck vessels (grades 3–5) were reported in
5p a t i e n t s( o n eg r a d e3 ,o n eg r a d e4 ,a n d3g r a d e5 ) ;
four of these patients were previously irradiated in the
head and neck area. In conclusion this study showed a
limited activity of sunitinib in the treatment of recurrent or
metastaticHNSCCwhilereportingasigniﬁcantriskofsevere
hemorrhage.4 Journal of Oncology
Sorafenib is the other small tyrosine kinase inhibitor
testedinthesamesetting.Itisamultitargetdrugwithactivity
against the EGFR-Ras-Raf-Mek-Erk signaling pathway and
against VEGF-VEGFR.
In the ﬁrst study, published in 2007 [45], Elser et al.
conducted a single-arm phase II study in patients aﬀected by
recurrent or metastatic HNSCC (including nasopharyngeal
carcinoma) that had previously received no more than one
systemic treatment. The trial enrolled 28 patients, treated
with sorafenib 400mg twice daily continuously, 27 evaluable
for eﬃcacy. The primary objective was ORR. The ORR
was 3.7%, while 37% of patients achieved a stabilization
of disease as best response. Median TTP was 1.8 months;
median OS time was 4.2 months. The most common grade 3
toxicities were lymphopenia (17%) and fatigue (7%).
The other published study, with sorafenib in ﬁrst-
line setting, was conducted on patients with persistent,
recurrent, or metastatic HNSCC [46]. The primary endpoint
was response probability. Sorafenib was administered as
continuoustreatment,400mgtwicedaily.Forty-onepatients
were eligible for response; one patient had a conﬁrmed PR
(2%). The estimated median PFS was 4 months, and the
estimated OS was 9 months. The most common grade 3
adverse events were hand-foot syndrome (7.3%), stomatitis
(4.8%), and nausea (4.8%). The only grade 4 event was
a cerebral ischemia caused by asymptomatic pulmonary
embolism.
The two studies demonstrated that sorafenib is well
tolerated in this population of patients. No signiﬁcant
activity was demonstrated in terms of response rate, but we
must consider that these novel drugs have often a cytostatic
eﬀects with limited cytotoxic activity. It is interesting to note
thatthetrialsconductedonchemonaivepatientsshowedPFS
and OS comparable to those achieved with more toxic and
aggressive regimens based on platinum and taxanes.
A further antiangiogenic agent tested in recurrent and
metastatic setting is the monoclonal antibody bevacizumab
directed against VEGF. It was administered in association
with erlotinib, an anti-EGFR inhibitor, to patients with
recurrent or metastatic HNSCC never treated or previously
treatedwithonelineofchemotherapy[47].ItwasaphaseI/II
study in which the authors used the association of an anti-
vascularagentandananti-EGFRone;thereareinfactseveral
trials in other cancers demonstrating that the use of these
type of drugs together improves eﬃcacy [48–53]. The phase
I study was designed to determine the maximum tolerated
dose of bevacizumab when associated to erlotinib: erlotinib
was given at dosage of 150mg/daily, while bevacizumab
was administered in escalating dose cohorts. The primary
o b j e c t i v eo ft h ep h a s eI Is t u d yw a sO R Ra n dT T P ;i n
this phase bevacizumab 15mg/kg was administered every
3 weeks. Forty-eight patients enrolled were evaluable for
response.Anobjectiveresponse(PRorCR)wasreportedin7
patients (15%), while 15 patients (31%) maintained stability
of disease. Four patients achieved a complete response with
a duration of response that lasted up to 17 months in
one patient. The median PFS was 4.1 months, and the
OS was 7.1 months. The treatment was well tolerated.
Grade 3 adverse events reported were esophagitis (1 patient),
diarrhea (1 patient), and lymphopenia (1 patient). There
was one grade 4 hemorrhage. In this study the association
was well tolerated with an interesting activity if com-
pared to trials with antiangiogenic agents used alone. The
authors also conducted an exploratory study to investigate
biomarkers that could predict clinical outcomes and ﬁnd
that high phosphorylated VEGFR2/VEGFR2 and endothelial
cells phosphorylated EGFR/EGFR ratios in baseline tumor
specimen can identify patients with the greatest probability
of response to erlotinib and bevacizumab.
With regard to locoregionally advanced disease, few
studies have just been published.
S e i w e r te ta l .[ 54] added bevacizumab to ﬂuorouracil
and hydroxyurea-based chemoradiotherapy in patients with
relapsed previously irradiated HNSCC or with poor prog-
nosis newly diagnosed disease. It was a phase I study to
determine the maximum tolerated dose of bevacizumab
when added to chemoradiotherapy. Forty-three patients
were enrolled: 29 patients (67.4%) were previously irra-
diated, while 14 patients (32.6%) were newly diagnosed.
Dose-limitingtoxicitieswerereachedatlevel3(bevacizumab
5mg/kg),soatlevel4(bevacizumab10mg/kg),thedosageof
chemotherapeutic agents alone was reduced. The treatment
was well tolerated with grade 3 mucositis occurring in 69.8%
of patients and grade 3 radiation dermitis in 11.6%. The
adverse events probably related to bevacizumab were grade
3 hypertension in 3 patients, 1 allergic rash reaction, 2 deep
vein thrombosis, 1 stroke, and 2 fatal hemorrhages. The
medianOSofthepatientsenrolledwas10.7months.Patients
with no prior radiation had a signiﬁcantly longer OS (40.1
months) than those previously irradiated (10.3 months).
This study demonstrates that bevacizumab 10mg/kg every
two weeks can be safely integrated to ﬂuorouracil and
hydroxyurea-based concomitant chemoradiotherapy: the
rate of severe complication was similar to those reported in
trials with diﬀerent agents in cohorts of patients with the
same characteristics [55–68].
Two more interesting studies were presented in the form
of abstractatthe 2009 ASCOannual meetings aspreliminary
results.
In the ﬁrst trial [68] the authors treated 60 patients with
newly diagnosed locoregionally advanced HNSCC with two
courses of induction chemotherapy repeated every 21 days
consisting of carboplatin AUC 6 day 1, paclitaxel 200mg/mq
day 1, 5 ﬂuorouracil200mg/mq/day continuous infusion
every 3 weeks, and bevacizumab 15mg/kg day 1 followed by
radiotherapy and concomitant paclitaxel 50mg/mq/weekly,
bevacizumab 15mg/kg weeks 1 and 4, and erlotinib 150mg
daily for 7 weeks. Forty-one patients (85%) completed all
treatments with an objective response rate of 77%. This
study has a short followup but interesting 18 months
PFS of 85% and 18 months OS of 87%. Severe toxicity
during induction chemotherapy was neutropenia (46%),
neutropenic fever (6%), mucositis (14%), diarrhea (14%),
and hand/foot syndrome (11%), while during concomitant
treatment severe mucositis was experienced by 76% of
patients.
In another trial [69] bevacizumab 15mg/kg days 1, 15,
and 43 and cisplatin 50mg/mq days 1, 2, 22, 23, 43, and 44Journal of Oncology 5
were added to deﬁnitive IMRT in patients with previously
untreated, stage III/IV, HNSCC. All patients completed
the treatment with a locoregional control rate of 100%
(3 patients developed distant metastases). Estimated one-
year PFS was 83% and estimated one-year OS 88%. The
main severe toxicities were mucositis (76%), nausea (24%),
vomiting (17%), neutropenia (41%), hemoglobin (17%),
hyponatremia (14%).
Table 1 summarize the main published clinical trials on
anti-angiogenetic drugs.
5.Mechanism of Resistance to Antiangiogenic
Treatment andFutureDirection
In many clinical trials anti-angiogenetic drugs have a lim-
ited eﬃcacy, especially in terms of overall survival. Some
authors [70, 71] demonstrated in their laboratories that
VEGF-targeted drugs inhibit the growth of primary tumors
but may shorten survival of mice by promoting tumor
invasiveness and the metastatic process. Ebos et al. [70]
tested the role of sunitinib in developing metastasis in mice
models. They selected sunitinib because of the schedule of
administration in clinical practice (4 weeks on/2 weeks oﬀ)
and the preliminary observations that tumor regrowth can
occur during rest period [72]. They showed that sunitinib
inoculatedindiﬀerentschedulesanddosesandwithdiﬀerent
tumor cell models can lead to opposite results on tumor
growth. For example, sustained treatment of pre-established
tumors inhibits its growth, while short-term treatment prior
to tumor inoculation results in the acceleration of metastasis
and reduction in survival. P` aez-Ribes et al. demonstrated
in the same issue of Cancer Cells [71] that two diﬀerent
mouse models of tumors, pancreatic neuroendocrine cancer
(PNET) and glioblastoma multiforme, can develop an adap-
tive and evasive response to an eﬃcacious antiangiogenic
treatment.Thisleadstoamoreaggressivebehavior,increased
dissemination, and distant metastasis progression. In PNET
models two diﬀerent drugs were tested, sunitinib and a
speciﬁc VEGFR2 inhibitor. Sunitinib had signiﬁcantly better
eﬃcacy than the competitor but surprisingly led to the
development of more invasive tumors.
So, how can these diﬀerent eﬀects of treatment with
angiogenic inhibitors be explained? First of all these agents
act by inducing hypoxia, but tumor cells are often able
to survive in hypoxic conditions thanks to the ability of
producing energy in the absence of oxygen [73]. So hypoxia
selects those cells that are more malignant and less sensitive
to treatment with these classes of agents [74].
Moreover, tumors can activate more vascular supply
mechanisms through upregulation of proangiogenic stromal
cells (ﬁbroblasts, pericytes, mesenchimal and hematopoietic
cells)thatcontributetothevasculaturescaﬀold.Antivascular
agents cause acute hypoxia that leads to the accumulation of
endothelial progenitors cells at the tumor margins [75]. Both
macrophagesandneutrophils inproximity ofhypoxictissues
can contribute to angiogenesis, escaping the mechanism of
action of the drugs [76, 77]. Furthermore hypoxia caused
by antiangiogenic treatments causes an increase in bone
marrow-derived cells consisting in vascular progenitors and
pro-angiogenic monocytic cells (monocytes, hemangiocytes
VEGFR-1+ and CD11b+ myeloid cells) [78–82], all involved
in the activation of angiogenesis-expressing cytokines,
growthfactors,andproteases[83,84].CD11b+Gr1+cellsare
wellknownfortheirabilitytoconferresistancetoanti-VEGF
in mouse models. These cells derive from bone marrow, are
presentathighlevelintumorandperipheralbloodoftumor-
bearinganimals[85],andproduceseveralangiogenicfactors,
such as Bv8 [86].
In addition VEGF-inhibitors induce an inﬂammatory
state characterized by the production of several cytokines
(PlGF, G-CSF, IL-6, erythropoietin, osteopontin) that stim-
ulate angiogenesis and metastasis in a VEGF-independent
manner[87].Anotherpossiblemechanismisthatanti-VEGF
agents or the cytokines induced by their action could inhibit
the action of pericytes on tumor vessels, making them more
leaky and immature and facilitating the intravasation of
tumor cells and metastatic spread [88].
The results achieved with antiangiogenic treatment are
sometimes controversial, but we must take into account
the several variables involved, such as VEGF levels, vessel
number, and function, VEGF-dependence of tumor vas-
cularization, pericyte action, recruitment and activation of
bonemarrow-derivedcells,targetanddurationoftreatment,
and the combination with diﬀerent cytotoxic agents. In
conclusion it is time to further investigate how to optimally
use these agents, with the aim of blocking the tumor growth
while suppressing prometastatic eﬀects.
6. Discussion
The review of the main studies published in the last years
conﬁrms the central role of angiogenesis in the growth and
progression of head and neck tumor [18]. Moreover, most
of the published data point to the relationship between
VEGF overexpression, more advanced disease at diagnosis,
and poor prognosis [10–17].
Despite the importance of angiogenesis in head and
neck cancer, few antiangiogenic agents have shown relevant
activityinthisclinicalsetting andhavebeenapprovedforthe
treatment of this disease.
The reason depends mainly on the fact that many studies
have been conducted on xenograft models. First of all some
data suggest the existence of two diﬀerent pathways in
angiogenesis [18], so it is mostly important to understand
as better as possible the pathogenetic process in each patient,
in order to select the correct therapeutic target.
Secondly, the lack of activity can be explained consider-
ing that some authors [33] demonstrated that angiogenesis
inhibition is probably not enough to completely arrest the
growth of tumors; then we should likely combine this
approach with cytotoxic drugs or other treatment such as
radiotherapy or anti-EGFR agents [29, 31, 32].
Furthermore,therearemanypreclinical datathatsuggest
that antiangiogenic treatments could be eﬀective on primary
tumors’ growth while promoting the developing of more
aggressive disease with a greater prometastatic behavior [70–
72].6 Journal of Oncology
Table 1: Clinical trials with antiangiogenic drugs.
Regimen Setting No. of
patients Results
Sunitinib [42] Recurrent/metastatic (ﬁrst line) 22 RDC 33% (terminated after interim analysis)
Sunitinib [43] Recurrent/metastatic (ﬁrst line) 17 Terminated for lack of eﬃcacy
Sunitinib [44] Recurrent/metastatic (platinum
refractory) 38 RDC 50%. mPFS 2 months, mOS 4 months
Sorafenib [45] Recurrent/metastatic (second line) 28 ORR 37%. mOS 4.2 months
Sorafenib [46] Recurrent/metastatic (ﬁrst line) 41 mPFS 4 months. Estimated OS 9 months
Erlotinib+bevacizumab [47] Recurrent/metastatic (ﬁrst/second
line) 48 RR 15%. mPFS 4.1 months. mOS 7.1 months
Bevacizumab+ﬂuorouracil+hydroxyurea
and radiotherapy [54]
Locally advanced relapsed or poor
prognosis newly diagnosed 43 mOS 10.7 months
Carboplatin+paclitaxel+5 ﬂuororuracil+
bevacizumab followed by radiotherapy+
paclitaxel+bevacizumab+erlotinib [68]
Locally advanced (ﬁrst line) 60 ORR 77%. 18 months PFS 85%, 18 months OS
87%
Bevacizumab+cisplatin+IMRT [69] Locally advanced (ﬁrst line) 42 Locoregional control rate 100%. Estimated 1
year PFS 83%; estimated 1 year OS 88%
RDC: rate of disease control; mPFS: median progression-free survival; mOS: median overall survival; ORR: overall response rate.
As for the trials concluded in patients with relapsed
or metastatic disease, the drugs that are more extensively
studied are TKI inhibitors, Sunitinib and Sorafenib.
Sunitinib [42–44] as monotherapy has shown limited
activity in these patients, and so no more studies are
warranted. Sorafenib [45, 46] did not give encouraging
results with regard to objective response but interesting data
of PFS and OS when used as ﬁrst-line treatment. Few studies
have just been concluded and published in patients with
locoregionally advanced disease [67, 68], and the results of
these trials have to be conﬁrmed with a longer followup.
Finally, it should be interesting to investigate whether the
expression of angiogenic factors can be used as predictive.
To date only one study [47] with a combination of an
antiangiogenic agent and an anti-EGFR inhibitor reported
a possible role of a molecular biomarker that could pre-
dict a greater possibility of response to an antiangiogenic
treatment. Further studies are needed to understand the
mechanisms of response and resistance to angiogenesis
inhibitors, how to integrate antiangiogenic therapies in the
treatments of patients aﬀected by HNSCC, and how to
identify those most likely to respond, in order to oﬀer the
best treatment for each patient while limiting toxicities.
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